Genetic Engineering and Biotechnology news articles take some time to load
The partnership’s first phase will see a review of the current medicines landscape conducted to identify opportunities for innovation. This information will be used to find systemic gaps in brain-entry technologies.
In this episode of GEN's Touching Base, editors discuss a variety of news including the halt of a lead pipeline program at Fulcrum Therapeutics, a new multibillion dollar collab, protein modeling updates from Biohub, and new potential for vaccine development.
The workflow pairs Bio-Techne’s MauriceFlex imaged capillary isoelectric focusing fractionation system with Refeyn's TwoMP mass photometry platform to connect charge heterogeneity with molecular weight and aggregation at single‑molecule resolution.
TRIM, an integrated genome engineering platform that combines prime editing, gene knockouts, and large-scale chromosome engineering, enabled efficient stacking of multiple beneficial traits to accelerate precision breeding in monocot crops.
By tracking thousands of B cells across more than 100 germinal centers in mice, researchers revealed how the system produces highly effective antibodies, challenging the idea that antibody improvement is driven mainly by rare growth “bursts” among the most successful B cells.
In addition to producing pDNA, RNA, and LNP formulations, Wacker’s CRS team offers construct design services, including plasmid and RNA construct design as well as RNA engineering and optimization via partners.
Scientists created an AI tool that can help to reveal how genes function together inside human cells dependent on the cellular context, which could ultimately help to support the development of better diagnostics, biomarkers, and therapies.
Scientists developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice, which they paired with a CAR T strategy targeting VEGF that helps reduce side effects while preserving strong anti-tumor activity.
Breaking from the traditional plenary format, Bio-IT World Conference 2026 opened with intimate discussions on the personal, scientific, clinical, and policy challenges shaping rare disease research.
New AI‑designed miniproteins precisely modulate GPCR signaling and reveal a new "receptor diversion" microscopy-based screening system for targeting receptors long considered difficult to drug.
In this episode of GEN's Touching Base, editors celebrate the 50th episode. They discuss AI scientists and biotech news including stock drops, a lawsuit, and big-ticket collaboration.
Using a confined culture system (CCS), the team grew small intestine, colon, and stomach organoids from tiny spherical forms into centimeter-scale tubular forms nearly 10 times larger than previous methods.
David Baker’s latest company is making medicines for a huge protein family once deemed undruggable. A new study generated miniproteins that target GPCRs across a diversity of receptor families implicated in itch and pain, cancer, metabolic disorders, and migraine.
Preclinical studies revealed new insights into PI5P4K enzymes that help move cholesterol around cells, showing that without these enzymes, a cholesterol traffic jam occurs, blocking the cancer cell's ability to fuel tumor growth.
The company’s IPO filing came a day after Parabilis inked an up-to-$2.3 billion-plus strategic research collaboration with Regeneron Pharmaceuticals to discover and develop an initial five candidates encompassing “antibody-Helicon conjugates,” a new form of antibody-drug conjugates aimed at challenging and historically undruggable targets. Regeneron has agreed to purchase approximately $75 million of Parabilis common stock in a concurrent private placement, at 90% of the IPO price per share.
---- End of list of Genetic Engineering and Biology News Articles on this page 2 of 2 total pages ----